BenchSci

BenchSci aims to enhance the pace and effectiveness of life-saving research by providing scientists with advanced biomedical artificial intelligence (AI). Their vision is to exponentially increase the speed and quality of scientific research by leveraging AI technologies.

BenchSci has received support and investment from several prominent organizations, including F-Prime, Gradient Ventures (Google's AI fund), Inovia Capital, and TCV. These partnerships enable BenchSci to develop and deploy cutting-edge AI solutions in the biomedical field.

The company's platform is utilized by 16 out of the top 20 pharmaceutical companies, as well as more than 4,300 leading research centers worldwide. By leveraging their AI technology, BenchSci aims to accelerate scientific discoveries, streamline experimental processes, and ultimately contribute to advancements in medical treatments and therapies.

Through their platform, scientists can access and analyze vast amounts of biomedical data more efficiently, enabling them to make informed decisions and optimize their research strategies. BenchSci's AI capabilities help researchers identify relevant antibodies, compare results, and discover new insights, ultimately accelerating the pace of scientific discovery in the field of biomedicine.